TROG Cancer Research
Members Login   CQMS Login

Closed lung trials

Trials closed to recruitment

TROG 16.01 (NIVORAD) - A randomised phase II trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.

Primary sponsor: The University of Sydney
Collaborating groups: ALTG and TROG

TROG 13.01 (SAFRON II) - the aim of this study is to see if stereotactic body radiotherapy has an ‘acceptable’ level of side effects, and will also examine quality of life, cost effectiveness and resource use.

Primary sponsor: TROG
Collaborating group: Australasian Lung Cancer Trials Group

TROG 09.02 (CHISEL) - this study investigates whether radiotherapy given as three large doses over a period of two weeks (hypofractionated radiotherapy) is more effective than standard radiotherapy for patients with non-small cell lung cancer that has not spread beyond the lung.

Primary sponsor: TROG

Completed trials

TROG 03.07 - A Randomised Phase II Study of Two Regimens of Palliative Chemoradiation Therapy in the Management of Locally Advanced Non Small Cell Lung Cancer

TROG 99.05 - Tumour Volume as an Independent Prognosis Factor in Patients with Non-Small Cell Lung Cancer: A Protocol for a Progressive Database

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.